Evidence map›Paper›PMID 41533061›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Multicenter development and validation of a probability-based model to diagnose Lewy body disease using ¹²³I-meta-iodobenzylguanidine.

Kenichi Nakajima, Junji Komatsu, Takeshi Matsumura, Satoshi Orimo, Mitsuhiro Yoshita, Viviana Frantellizzi, Maria Silvia De Feo, Gemma Greenfinch, Alan Thomas, Roberta Assante and 7 more

Abstract readValidation StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kenichi NakajimaDepartment of Nuclear Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, 920-8640, Kanazawa, Japan. nakajima@med.kanazawa-u.ac.jp.ORCID 0000-0001-7188-8746
Junji KomatsuDepartment of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Takeshi MatsumuraDepartment of Nuclear Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, 920-8640, Kanazawa, Japan.
Satoshi OrimoKamiyoga-Setagaya Street Clinic, Tokyo, Japan.
Mitsuhiro YoshitaNational Hospital Organization (NHO) - Hokuriku National Hospital, Nanto, Japan.
Viviana FrantellizziDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy.
Maria Silvia De FeoDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy.
Gemma GreenfinchInstitute of Nuclear Medicine, University College London Hospital, London, UK.
Alan ThomasTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Roberta AssanteDepartment of Advanced Biomedical Science, University of Naples Federico II, Naples, Italy.
Wanda AcampaDepartment of Advanced Biomedical Science, University of Naples Federico II, Naples, Italy.
Naoki ShirasakiDepartment of Neurosurgery, Kaga Medical Center, Kaga, Japan.
Kunihiko YokoyamaPET Imaging Center, Public Central Hospital of Matto Ishikawa, Hakusan, Japan.
Hiroshi WakabayashiDepartment of Nuclear Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, 920-8640, Kanazawa, Japan.
Moeko Noguchi-ShinoharaDepartment of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Kenjiro OnoDepartment of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Seigo KinuyaDepartment of Nuclear Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, 920-8640, Kanazawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe previously proposed that a probability-based sympathetic

methodsWe compared data from 967 patients with suspected LBD with 62 controls from a normal database (NDB). Of 815 patients with guideline-based diagnoses, 483 had LBD (Parkinson disease [PD] or dementia with Lewy bodies [DLB]) and 332 did not have LBD. Heart-to-mediastinum (H/M) ratios were standardized using a phantom-based method. Logistic regression models included early and late H/M ratios, age, sex, and comorbidities. We assessed diagnostic performance using ROC analysis and cross-validation.

resultsThe updated model discriminated LBD from other diseases (AUC for early and late H/M, 0.880 0.899, respectively). Age correction of H/M ratios based on the NDB did not improve accuracy. Median early H/M ratios [SMILe probability] were 3.09 [12.8%] for NDB, 2.57 [37.5%] for Alzheimer disease, 1.76 [84.7%] for PD, and 1.62 [89.0%] for DLB, with significantly lower H/M ratios and higher probabilities in PD and DLB compared with controls (p < 0.0001). Late-phase imaging added value mainly in intermediate borderline (30%-70%) situations. Coronary artery disease attenuated the diagnostic performance of SMILe.

conclusionThe probability-based

Indexed as

3-IodobenzylguanidineLewy Body DiseaseAgedAged, 80 and overFemaleHumansMaleProbabilityRadiopharmaceuticals3-IodobenzylguanidineRadiopharmaceuticalsDementia with Lewy-bodiesDiagnostic modelParkinson diseaseSympathetic index

Identifiers

PMID41533061
PMCPMC13013391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.